AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences

AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences

Source: 
Medical Marketing and Media
snippet: 


AstraZeneca has in-licensed CMG901, an experimental antibody drug conjugate (ADC) for treating gastric cancer, from China-based biotech KYM Biosciences, firms said Thursday.